NCT00698464View on ClinicalTrials.gov

Pharmacokinetics and Safety of Single Subcutaneous Pasireotide (SOM230) in Subjects With Varying Degrees of Hepatic Function

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

April 30, 2009

Conditions
Hepatic CirrhosisAlcoholism
Interventions
DRUG

Pasireotide

Single subcutaneous injection of 600 µg of Pasireotide.

Trial Locations (4)

23249

McGuire Research Institute VAMC, Richmond

Unknown

Universite Catholique de Louvain, Brussels

Novartis Investigative site, Berlin

Novartis Investigative Site, George

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY